fractional dose HPV vaccine

The fractional dose HPV vaccine refers to a reduced-dose regimen (one-fifth of the standard dose) of existing human papillomavirus (HPV) vaccines, specifically the bivalent Cervarix (GSK) and the nonavalent Gardasil 9 (Merck). This dosing strategy is being evaluated in a Phase IV clinical trial led by the University of Washington to assess its immunogenicity when administered via intramuscular or intradermal routes in adults aged 27-45. The vaccines are composed of virus-like particles (VLPs) derived from the L1 major capsid protein of various HPV types. Cervarix targets high-risk types 16 and 18 and utilizes the AS04 adjuvant system, while Gardasil 9 targets types 6, 11, 16, 18, 31, 33, 45, 52, and 58 with an aluminum-based adjuvant. The primary goal of investigating fractional doses is to potentially extend vaccine supply and reduce costs while maintaining protective antibody responses against HPV infection and related cancers.

Other names

HPV vaccine-University of Washington-human papillomavirus infection1/5 dose HPV vaccinefractional dose bivalent HPV vaccinefractional dose nonavalent HPV vaccine